NCT02005757Unknown2 期
Open Label, Multicenter, Randomized Study to Assess the Efficacy and Safety of Mizoribine in Active Rheumatoid Arthritis Patients Unsuccessfully Treated With Disease-modifying Antirheumatic Drug
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 60
- 试验地点
- 7
- 主要终点
- all cause mortality
研究概览
简要总结
The purpose of this study is to access the efficacy and safety of Mizoribine 150mg qid and 50mg tid in active rheumatoid arthritis patients unsuccessfully treated with disease-modifying antirheumatic drug.
详细描述
- EULAR Response after 24weeks of treatment
- EULAR Response after 12weeks of treatment
- DAS28 value change
- KHAQ-20 value change
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female aged from 20 to 80 years old
- •Signed and dated informed consent document indicating that the patient
- •Patients must have a diagnosis of Rheumatoid Arthritis(RA) of at least 3months duration as defined by the 2010 American College of Rheumatology(ACR) Classification criteria.
- •Patients should have a Disease Activity Score 28 greater than or equal to 3.2 (DAS28 ≥ 3.2) and have received treatment with more than 1 kind of disease-modifying antirheumatic drug(including MTX).
- •ESR≥28mm/h or CRP≥1.0mg/dl at screening.
- •Exclusion Criteria
- •At screening, patients have laboratory result as defined by : white blood cell ≤ 3,000/mm3
- •, Hemoglobin < 8.5 g/dL, Platelet count < 100,000/mm3, Serum creatinine > 2.0 mg/dL, Aspartic Acid Transaminase/Alanine Transaminase ≥ 2*upper limit of normal , Uric acid ≥ 1.5*upper limit of normal
- •Patient must not have bleeding disorder or taking anticoagulant. (But, lt is allowed to take 100mg/day of Asprin)
- •Patients with a history of operation on index knee joint which could have influence on the result and need to have surgery as determined by investigator.
- •Patients have severe infection, including moderate respiratory disease and have received treatment with systemic antibiotics within 2 weeks.
- •Patients have cardiovascular disease or associated disease which is not controlled.
- •Patients have a history of malignancy within 5years. (But, basal cell or squamous cell carcinoma or carcinoma in situ of the uterine cervix have been treated is allowed)
- •Patients have hypersensitivity reaction on this drug.
- •Patients on any other clinical trial or experimental treatment in the past 3months.
- •Female patients who are breast feeding, pregnant or plan to become pregnant during the trial or for two months following study termination.
- •Not allowable medication recorded below ; Intra-articular injections within weeks at baseline visit, Patients taking oral steroid over 10mg /day or using new treatment or changing dosage within 4weeks at baseline visit, Using new nonsteroidal antiinflammatory drug within 4 weeks or changing nonsteroidal antiinflammatory drug dosage within 2 weeks at baseline visit.
- •Having experience of use biologic agent, immunosuppressant, cytostatic preparations within 8weeks at baseline visit. (But, Rituximab is not allowed within 6months)
- •Start to treatment new disease-modifying antirheumatic drug or need to change dosage of disease-modifying antirheumatic drug which is taking on the trial. (Leflunomide(ARAVA®) is not allowed within 12weeks, But, Cholestyramine is allowed after 48 hours later stopping. if it use three times a day, 8g, for 11days)
排除标准
- 未提供
研究组 & 干预措施
Bredinin tablet 150mg
Experimental
dosage form: Tablet, dosage: 150mg qd, Duration: for 6months
干预措施: Bredinin tablet 150mg (Drug)
Bredinin tablet 50mg
Active Comparator
dosage form: Tablet, dosage: 50mg tid, Duration: for 6months
干预措施: Bredinin tablet 50mg (Drug)
结局指标
主要结局
all cause mortality
时间窗: two years
次要结局
未报告次要终点
研究者
研究点 (7)
Loading locations...
相似试验
终止
3 期
Study of Combination Therapy With LdT Plus Adefovir Versus Adefovir AloneHepatitis BNCT00376259Novartis43
已完成
3 期
An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)Diabetes Mellitus, Type 2NCT00094757Merck Sharp & Dohme LLC521
已完成
3 期
Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) PatientsAge Related Macular DegenerationNCT00826371Novartis Pharmaceuticals114
尚未招募
1 期
Mesenchymal Stem Cell Therapy for Knee OsteoarthritisOsteoarthritis, KneeNCT05288725Next Generation Regenerative Medicine LLC120
终止
3 期
Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson DiseaseWilson DiseaseNCT05047523Alexion Pharmaceuticals, Inc.40